Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

Clinical & Translational Oncology 2026

View at publisher
Authors: Salih Tünbekici, Hamit Bal, Oğuzcan Kınıkoğlu, Hayati Arvas, Harun Muğlu, Ahmet Erkan Bilici, Mustafa Seyyar, Halil Goksel Guzel, Banu Öztürk, Özge Yalıcı, Duygu Özaşkın, Ramazan Coşar
+37 more Fatmagül Çıkladilmez, Evrican Zin, Aytac Terzi, Tugce Ulasli, Taha Koray Şahin, Denız Can Guven, Gamze Serin Özel, Merve Bıyıklı Alemdar, Bilgin Demir, Ali̇ Kalem, Pervin Can Sanci, Kazım Uygun, Elif Şahin, Teoman Şakalar, Ali Kaan Güren, Gokhan Ozturk, Enes Yeşilbaş, Tuğçe Kübra Güneş, Burcu Belen, Muzaffer Uğraklı, Kursat Dıslı, Ahmet Fatih Oruç, Melek Karakurt Eryılmaz, Ismet Culcuoglu, Mustafa Ersoy, Bahadır Köylü, Fatih Selçukbırıcık, Oğuzhan Yıldız, Mehmet Emin Yılmaz, Saadettin Kılıçkap, Ertuğrul Bayram, Caner Acar, Gokhan Şahin, Haydar Çağatay Yüksel, Mustafa Murat Mıdık, Pınar Gürsoy, Erdem Göker
DOI: 10.1007/s12094-026-04228-5
Cited by: 0
References: 25

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment Lung Cancer Research Studies

Publication details

Journal / source
Clinical & Translational Oncology
Volume
28
Issue
8
Pages
3160–3169
Publication date
11 February 2026
Language
EN